Monjuvi Prices, Coupons, Copay Cards & Patient Assistance
Monjuvi (tafasitamab) is a member of the CD19 monoclonal antibodies drug class and is commonly used for Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Monjuvi prices
Intravenous Powder For Injection
200 mg Monjuvi intravenous powder for injection from $1,500.12 for 1 powder for injection
Quantity | Per unit | Price |
---|---|---|
1 | $1,500.12 | $1,500.12 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Get your FREE Drugs.com Discount Card
Save up to 80% off the cost of prescription drugs and OTC medicines valid at over 65,000 pharmacies.
This is a drug discount program, not an insurance plan.
Monjuvi Coupons, Copay Cards and Rebates
Monjuvi offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
IncyteCARES for MONJUVI Savings Program
Eligible commercially insured patients may pay as little as $0 per prescription with a maximum savings of up to $25,000 per calendar year.
- Applies to:
- Monjuvi
- Number of uses:
- per prescription per calendar year
Form more information phone: 855-452-5234 or Visit website
Patient Assistance & Copay Programs for Monjuvi
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Monjuvi (tafasitamab-cxix) Injection; IV
More information please phone: 866-316-7263 Visit website
Provider: IncyteCARES for Monjuvi Patient Assistance Program
Eligibility requirements:- Must be uninsured or underinsured
- Varies
- FDA-approved diagnosis
- Must be residing in the US or Puerto Rico
- Patient or doctor's office can call the program to apply. Patient must sign the enrollment form to give the program permission to access their financial information in order to determine eligibility. Conditional approval for 90 days. Education and support services are available. This program also provides copay/coinsurance assistance for commercially/privately insured patients Prescribers can enroll the patient online via the IncyteCARES.com website. This program may provide a Bridge Program for eligible patients who experience a delay, temporary loss, or change in coverage. Contact program for details.
- Monjuvi (tafasitamab-cxix) Injection; IV
More information please phone: 855-421-6172 or 855-452-5234 Visit website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
Rituxan
Rituxan is used to treat certain leukemias and lymphomas and some non-cancer conditions, such as ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Breyanzi
Breyanzi is a CAR T cell therapy for large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle ...
Kymriah
Kymriah is used to treat B-cell precursor acute lymphoblastic leukemia (ALL), large B-cell ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma (FL) in adults. It is a p ...
Zynlonta
Zynlonta (loncastuximab tesirine) is used to treat relapsed or refractory diffuse large B-cell ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Tazverik
Tazverik (tazemetostat) used for the treatment of patients with epithelioid sarcoma and follicular ...
More about Monjuvi (tafasitamab)
- Check interactions
- Compare alternatives
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD19 monoclonal antibodies
- Breastfeeding
- En español